Motixafortide acetate is under clinical development by BioLineRx and currently in the Phase I, Phase II and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Motixafortide acetate’s likelihood of approval (LoA) and phase transition for Gastric Cancer took place on 22 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 22 Jul 2022 increased Motixafortide acetate’s Phase Transition Success Rate (PTSR) for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), increased PTSR for Myelodysplastic Syndrome, and increased PTSR for Pancreatic Ductal Adenocarcinoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Motixafortide acetate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Motixafortide acetate overview

Motixafortide is under development for the treatment of hematological cancers including chronic myeloid leukemia, metastatic adenocarcinoma of the pancreas, non-Hodgkin's lymphoma, neuroblastoma, melanoma, thrombocytopenia, aplastic anemia (AA), gastric cancer, adenocarcinoma of gastric or gastroesophageal junction, hypoplastic myelodysplastic syndrome, metastatic pancreatic adenocarcinoma, small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, multiple myeloma, sickle cell disease and acute respiratory distress syndrome (ARDS) secondary to COVID-19, acute myeloid leukemia and other respiratory viral infections. The drug candidate is administered through subcutaneous and intravenous route. BL-8040 is a short peptide. It acts by targeting chemokine (C-X-C Motif) receptor 4 (CXCR4). The company was developing relapsed/refractory acute myeloid leukemia (AML) and squamous non-small cell lung cancer (first and third-line therapy), hematopoietic stem cell transplantation.

BioLineRx overview

BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML), and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx‘s only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in-Maccabim-Re’ut, Israel.

Quick View Motixafortide acetate LOA Data

Report Segments
  • Innovator
Drug Name
  • Motixafortide acetate
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Oncology
Key Developers
  • Sponsor Company: BioLineRx
  • Originator: Hadasit Medical Research Services and Development and Kyoto University
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.